These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 26690800)
21. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Galvin JE Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599 [TBL] [Abstract][Full Text] [Related]
22. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Paleologou KE; Irvine GB; El-Agnaf OM Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056 [TBL] [Abstract][Full Text] [Related]
23. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687 [TBL] [Abstract][Full Text] [Related]
24. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850 [TBL] [Abstract][Full Text] [Related]
25. Seeking a mechanism for the toxicity of oligomeric α-synuclein. Roberts HL; Brown DR Biomolecules; 2015 Mar; 5(2):282-305. PubMed ID: 25816357 [TBL] [Abstract][Full Text] [Related]
26. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]
27. Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons. Ulusoy A; Björklund T; Buck K; Kirik D Neurobiol Dis; 2012 Sep; 47(3):367-77. PubMed ID: 22659302 [TBL] [Abstract][Full Text] [Related]
28. Triptolide Promotes the Clearance of α-Synuclein by Enhancing Autophagy in Neuronal Cells. Hu G; Gong X; Wang L; Liu M; Liu Y; Fu X; Wang W; Zhang T; Wang X Mol Neurobiol; 2017 Apr; 54(3):2361-2372. PubMed ID: 26957304 [TBL] [Abstract][Full Text] [Related]
29. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Bosco DA; Fowler DM; Zhang Q; Nieva J; Powers ET; Wentworth P; Lerner RA; Kelly JW Nat Chem Biol; 2006 May; 2(5):249-53. PubMed ID: 16565714 [TBL] [Abstract][Full Text] [Related]
30. N(ɛ)-(carboxymethyl)lysine linkage to α-synuclein and involvement of advanced glycation end products in α-synuclein deposits in an MPTP-intoxicated mouse model. Choi YG; Lim S Biochimie; 2010 Oct; 92(10):1379-86. PubMed ID: 20624443 [TBL] [Abstract][Full Text] [Related]
31. Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein. Bae EJ; Ho DH; Park E; Jung JW; Cho K; Hong JH; Lee HJ; Kim KP; Lee SJ Antioxid Redox Signal; 2013 Mar; 18(7):770-83. PubMed ID: 22867050 [TBL] [Abstract][Full Text] [Related]
33. Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. McCormack AL; Di Monte DA Curr Protein Pept Sci; 2009 Oct; 10(5):476-82. PubMed ID: 19538156 [TBL] [Abstract][Full Text] [Related]
34. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595 [TBL] [Abstract][Full Text] [Related]
38. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases. Chavarría C; Souza JM Arch Biochem Biophys; 2013 May; 533(1-2):25-32. PubMed ID: 23454347 [TBL] [Abstract][Full Text] [Related]
39. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. Villar-Piqué A; Lopes da Fonseca T; Outeiro TF J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401 [TBL] [Abstract][Full Text] [Related]
40. DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells. Jinsmaa Y; Sullivan P; Sharabi Y; Goldstein DS Auton Neurosci; 2016 Jan; 194():46-51. PubMed ID: 26777075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]